Median Technologies (ALMDT) AI Stock Analysis

• Market Cap: €41.33M
• Dividend Yield: N/A
• Average Volume (3M): 262.28K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.22
• Revenue Growth: 3.25%
• EPS Growth: -2.07%
• Country: FR
• Employees: 225
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Devices
• EPS (TTM): -0.69
• Shares Outstanding: 19,889,025
• 10 Day Avg. Volume: 323,921
• 30 Day Avg. Volume: 262,281
• PEG Ratio: 0.31
• Price to Book (P/B): -1.23
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.19
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €1.00
• Price Target Upside: -51.92% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: €2.00 ▼(-3.85%Downside)

The most significant factor affecting the stock score is the challenging financial performance, marked by consistent losses and high leverage, leading to a low financial performance score. Technical analysis provides some optimism with a few positive indicators, but the overall trend is bearish. The valuation is unattractive due to negative earnings and no dividend yield, further contributing to the low overall score.

Median Technologies Business Overview & Revenue Model

Company Description

Median Technologies SA develops and markets software products and platforms for medical image analysis in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iBiops, an end-to-end AI-powered technology software as a medical device that integrates and optimizes the entire medical imaging workflow; and iSee for image analysis services in clinical trials. It also provides imaging contract research services, such as study start up, image and clinical data management, scientific consulting, independent reviews, image data processing and site support, and study close-out for studies. Median Technologies SA has a research collaboration agreement with the University of California. The company was founded in 2002 and is based in Valbonne, France.

How the Company Makes Money

Median Technologies generates revenue through the sale and licensing of its medical imaging software solutions to healthcare providers, research institutions, and pharmaceutical companies. The company offers its products as subscription-based services, allowing clients to access its software platforms for a recurring fee. Additionally, Median may engage in strategic partnerships with pharmaceutical companies for clinical trials, providing imaging analysis services that support drug development and regulatory approval processes. These collaborations can lead to significant revenue streams through long-term contracts and service agreements. Furthermore, the company's investments in research and development enable it to continuously innovate and maintain a competitive edge in the market, contributing to its revenue growth.

Median Technologies Financial Statement Overview

Summary

Median Technologies is experiencing significant financial challenges. The income statement reveals declining profitability with persistent negative margins. The balance sheet shows financial distress with negative equity, and cash flow analysis indicates unsustainable operations, all suggesting a need for strategic financial restructuring.

Income Statement

Median Technologies has faced declining revenue and profitability over recent years. Despite some growth in revenue from 2020 to 2024, the company has consistently reported negative gross and net profit margins. The EBIT and EBITDA margins are also negative, indicating operational challenges. The negative net income and declining revenue growth rate highlight ongoing financial struggles.

Balance Sheet

The company's balance sheet shows significant financial distress, with a negative stockholders' equity, indicating more liabilities than assets. The debt-to-equity ratio is not calculable due to negative equity, but the large amount of debt relative to assets points to high leverage. The equity ratio is negative, further underscoring financial instability.

Cash Flow

Median Technologies reports negative free cash flow, with a slight improvement in operating cash flow over recent years. The operating cash flow to net income ratio is negative, reflecting unsustainable operations. Free cash flow to net income is also negative, pointing to cash flow challenges that affect financial flexibility.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	22.95M	22.23M	23.67M	20.55M	13.48M
Gross Profit	-21.07M	-2.55M	24.42M	20.43M	13.34M
EBITDA	-19.28M	-19.59M	-17.48M	-16.94M	-11.21M
Net Income	-25.24M	-22.98M	-20.21M	-19.29M	-12.80M
Balance Sheet
Total Assets	24.37M	35.94M	34.75M	49.39M	25.28M
Cash, Cash Equivalents and Short-Term Investments	8.29M	19.63M	21.67M	39.25M	16.40M
Total Debt	29.44M	23.01M	18.15M	17.45M	4.37M
Total Liabilities	58.34M	46.23M	42.01M	44.45M	36.65M
Stockholders Equity	-33.97M	-10.29M	-7.25M	4.94M	-11.36M
Cash Flow
Free Cash Flow	-19.03M	-21.53M	-17.18M	-10.61M	-5.82M
Operating Cash Flow	-17.95M	-20.24M	-15.79M	-10.13M	-5.46M
Investing Cash Flow	-1.17M	-1.25M	-1.39M	-672.00K	-327.00K
Financing Cash Flow	7.67M	19.72M	-277.00K	33.20M	14.56M

Median Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.08
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALMDT, the sentiment is Negative. The current price of 2.08 is above the 20-day moving average (MA) of 1.93, above the 50-day MA of 2.03, and below the 200-day MA of 3.03, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 51.48 is Neutral, neither overbought nor oversold. The STOCH value of 17.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALMDT.

Median Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.34B	-0.07	-63.86%	2.34%	16.17%	0.23%
ALMDT	43 Neutral	€41.33M	―		―	3.25%	-2.07%
TCLIF	―	$20.99M	―	-199.44%	―	―	―
NVYTF	―	$38.42M	―	-57.82%	―	―	―
DMS1	―	€28.15M	―	-22.84%	―	―	―
9W8	―	€21.23M	―	-16.43%	―	―	―
0JZ	―	€49.55M	―	-47.78%	―	―	―